Impact of Vitamin D on Gut Microbiome and Metabolome Among Pediatric Oncology Patients
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07938333. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Brief Summary The purpose of this observational study is to better understand how vitamin D levels affect the gut microbiome (the bacteria that live in the intestines) in children who are newly diagnosed with acute lymphoblastic leukemia (ALL). Researchers want to learn whether low vitamin D levels are linked to changes in gut bacteria and whether this may affect how children with ALL respond to chemotherapy. The main questions this study aims to answer are: * Are the gut bacteria different in children with ALL who have low vitamin D levels compared to those with normal vitamin D levels at the time of diagnosis? * How do vitamin D levels relate to changes in gut bacteria and related body processes before and after induction chemotherapy? Researchers will compare children who have low vitamin D levels with those who have normal vitamin D levels to see if there are differences in their gut bacteria and how those bacteria change during early treatment. The stool samples will be studied in specialized laboratories to better understand how vitamin D and gut bacteria interact. The results of this study may help doctors understand whether monitoring and managing vitamin D levels could improve care and treatment outcomes for children with ALL. Participants will: Have four study visits: * Screening: Review and sign consent/assent forms, review of Inclusion/Exclusion Criteria, medical history, and current medications * At diagnosis (baseline): Review of medications, laboratory results, Vitamin D level, Fecal Sample Collection * Day 29-32 - At the end of induction chemotherapy: Review of medications, laboratory results, Vitamin D level, Fecal Sample Collection and Adverse event assessment * Day 90-97 after Induction: Review of medications, laboratory results, Vitamin D level, Fecal Sample Collection and Adverse event assessment
Study identification
- NCT ID
- NCT07938333
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 0 Years to 18 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 9, 2026 (Estimated)
- Primary completion
- Aug 31, 2027 (Estimated)
- Completion
- Dec 31, 2027 (Estimated)
- Last update posted
- Nov 16, 2026
2026 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital of Orange County | Orange | California | 92868 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07938333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 16, 2026 · Synced Nov 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.